Virginia Senate President L. Louise Lucas called out Maryland Senate President Bill Ferguson, who has opposed his state jumping into the national fray ...

Chandler High School football quarterback Will Mencl discusses where his head is at before his clash with Hamilton, and his approach to this season.

Republican Rep. Ken Calvert said he will run for a newly drawn Southern California district, setting up a possible clash with GOP Rep. Young Oak Kim.

If found guilty, the three people charged can’t have the charge reduced to a misdemeanor, meaning they’re facing the possibility of real prison time.

New peer-reviewed study shows significant real-world improvement in pressure-ulcer healing with advanced cellular, acellular, and matrix-like products compared to standard care. MISSOULA, MT / ACCESS ...

The National Bank of Egypt is proud of its strategic role in supporting Egyptian heritage. Hesham Talaat: GEM is a milestone that is reshaping Egypt’s cultural landscape and presenting the nation to ...

The weather is good, the fuel is ready, so Arizona forest managers are conducting prescribed burns in the coming weeks.

Company to Engage Industry Leaders on the Responsible Development of Wyoming’s Bison Basin Natural Gas Resources CASPER, WY / ACCESS Newswire / October 31, 2025 / Lost Soldier Oil and Gas (“Lost ...

VANCOUVER, BC / ACCESS Newswire / November 3, 2025 / CoTec Holdings Corp. (TSX-V:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to announce it has entered into an investor relations agreement ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study – Cash burn of $4.2 million in Q3 remains in line with ...

ORLANDO, FLORIDA / ACCESS Newswire / October 31, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip ...

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...